IPSC‐based modeling of THD recapitulates disease phenotypes and reveals neuronal malformation

dc.contributor.author
Tristá Noguero, Alba
dc.contributor.author
Fernández Carasa, Irene
dc.contributor.author
Calatayud, Carles
dc.contributor.author
Bermejo Casadesús, Cristina
dc.contributor.author
Pons Espinal, Meritxell
dc.contributor.author
Colini Baldeschi, Arianna
dc.contributor.author
Campa, Leticia
dc.contributor.author
Artigas Pérez, Francesc
dc.contributor.author
Bortolozzi, Analia
dc.contributor.author
Domingo Jiménez, Rosario
dc.contributor.author
Ibáñez, Salvador
dc.contributor.author
Pineda, Mercè
dc.contributor.author
Artuch Iriberri, Rafael
dc.contributor.author
Raya Chamorro, Ángel
dc.contributor.author
García Cazorla, Àngels
dc.contributor.author
Consiglio, Antonella
dc.date.issued
2023-05-23T09:59:43Z
dc.date.issued
2023-05-23T09:59:43Z
dc.date.issued
2023-02-06
dc.date.issued
2023-04-14T11:15:49Z
dc.identifier
1757-4684
dc.identifier
https://hdl.handle.net/2445/198344
dc.identifier
36740977
dc.description.abstract
Tyrosine hydroxylase deficiency (THD) is a rare genetic disorder leading to dopaminergic depletion and early-onset Parkinsonism. Affected children present with either a severe form that does not respond to L-Dopa treatment (THD-B) or a milder L-Dopa responsive form (THD-A). We generated induced pluripotent stem cells (iPSCs) from THD patients that were differentiated into dopaminergic neurons (DAn) and compared with control-DAn from healthy individuals and gene-corrected isogenic controls. Consistent with patients, THD iPSC-DAn displayed lower levels of DA metabolites and reduced TH expression, when compared to controls. Moreover, THD iPSC-DAn showed abnormal morphology, including reduced total neurite length and neurite arborization defects, which were not evident in DAn differentiated from control-iPSC. Treatment of THD-iPSC-DAn with L-Dopa rescued the neuronal defects and disease phenotype only in THDA-DAn. Interestingly, L-Dopa treatment at the stage of neuronal precursors could prevent the alterations in THDB-iPSC-DAn, thus suggesting the existence of a critical developmental window in THD. Our iPSC-based model recapitulates THD disease phenotypes and response to treatment, representing a promising tool for investigating pathogenic mechanisms, drug screening, and personalized management.
dc.format
15 p.
dc.format
application/pdf
dc.format
application/pdf
dc.language
eng
dc.publisher
EMBO
dc.relation
Reproducció del document publicat a: https://doi.org/10.15252/emmm.202215847
dc.relation
EMBO Molecular Medicine, 2023, vol. 15, num. 3, p. e15847
dc.relation
https://doi.org/10.15252/emmm.202215847
dc.rights
cc by (c) Tristá Noguero, Alba et al., 2023
dc.rights
http://creativecommons.org/licenses/by/3.0/es/
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject
Malalties rares
dc.subject
Cèl·lules mare
dc.subject
Fenotip
dc.subject
Dopamina
dc.subject
Rare diseases
dc.subject
Stem cells
dc.subject
Phenotype
dc.subject
Dopamine
dc.title
IPSC‐based modeling of THD recapitulates disease phenotypes and reveals neuronal malformation
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.